Overview

Stock Information

Symbol Market Last Change Volume
CGIX NASDAQ

View Stock Information

Latest Webcast

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Latest Press Releases

  • Dec11

    Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis Read More

  • Dec08

    Cancer Genetics Prices $7 Million Registered Direct Offering Read More

  • Nov30

    Cancer Genetics to Participate in Upcoming Investor Conferences Read More

Latest Events

  • Nov09

    3rd Quarter 2017 Conference Call
    Date: November 9, 2017

  • Aug22

    Investor and Analyst Call
    Date: August 22, 2017

  • Aug14

    2nd Quarter 2017 Conference Call
    Date: August 14, 2017
    Read More

Contacts

Company
Cancer Genetics, Inc.
201 Route 17 North
2nd Floor
Rutherford, NJ 07070

Investor Relations
201-528-9200
ir@cgix.com


Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Reports
Click here to login and view your reports.